APMA has the resources you need to help you through every step of your career. With detailed information about MIPS and recent coding trends along with compliance guidelines and practice marketing materials, APMA has you covered whether you are just getting started in practice, preparing for retirement, or anywhere in between.
Today's podiatrist has the necessary education and training to treat all conditions of the foot and ankle and plays a key role in keeping America healthy and mobile while helping combat diabetes and other chronic diseases.
Your feet are excellent barometers for your overall health. Healthy feet keep you moving and active. They are quite literally your foundation. In this section, learn more about APMA Seal-approved and accepted products, proper foot care, common foot and ankle conditions, and how your podiatrist can help keep you and your feet healthy.
APMA is the only organization lobbying for podiatrists and their patients on Capitol Hill. As the voice of podiatric medicine to your legislators and regulators, APMA is active on a variety of critical issues affecting podiatry and the entire health-care system.
Last week, APMA submitted comments to CMS in response to its proposed rules related to the Home Health Prospective Payment System (HHPPS) and Transitional Coverage for Emerging Technologies (TCET).
In the comments related to the HHPPS proposed rule, APMA focused largely on CMS’ proposal to create a new benefit category for “lymphedema compression treatment items.” APMA was generally supportive of CMS’s proposals related to this section. We also strongly recommended that CMS should make the professional services of applying these types of bandages a covered service, and supported finalizing CMS’ proposal to include accessories necessary for the effective use of gradient compression garments and gradient compression wraps with adjustable straps under this new benefit for lymphedema compression treatment items.
In the comments related to the TCET, APMA supported CMS’ revamped proposal to meaningfully create a new mechanism that would allow temporary Medicare coverage to certain qualifying devices designated by the Food and Drug Administration (FDA) as breakthrough devices, via the transitional coverage for emerging technologies (TCET) pathway. APMA recommended that CMS provide clearer guidelines for how it will prioritize nominations for acceptance into the TCET pathway. We also recommended that CMS provide additional clarification on how coding and payment processes to facilitate coverage and payment for new or emerging technologies will unfold.
To read both these letters and other past letters in full, visit www.apma.org/CommentLetters. Contact the APMA Health Policy and Practice department with any questions or concerns.
—
Learn MoreSignificant Changes to Steroid HCPCS Coding
—
Learn More11400 Rockville Pike, Suite 220
Rockville, MD 20852
301-581-9200
Contact Us
Copyright © 2024 American Podiatric Medical Association